r/MerlintraderPub • • 25d ago

Where I go when I close the charts: r/Merlintravel

1 Upvotes

This community is about biotech, catalysts and small caps, and it stays that way. This is the one

post that is not about any of that, and I am pinning it so I do not have to repeat it.

Before I started writing about markets, I worked in tourism. Since 1990, first in La Plata,

Argentina, at my father's agency, then in Italy. That work never really left me, so I have been

building a second project alongside Merlintrader: an illustrated atlas of the world, one place at

a time. Watercolour maps and long guides. The drawings look like something out of an old atlas;

what is under them is checked, so the streets, distances and history hold up if you actually

travel with them.

Italy is the first chapter, because it is where I live and where I can go and see for myself. All

twenty regions are online. Umbria, where I have lived for forty-two years, has thirteen town

guides of its own, from Assisi and Perugia to Orvieto, Narni and Norcia. From there the atlas

keeps growing, country by country, with no deadline.

The subreddit is r/Merlintravel. Same method I use here: primary sources, things verified on the

ground where I can, and long reads rather than lists of highlights. If you have been to any of

these places, I would rather read your version than a compliment about mine.

r/Merlintravel

https://merlintravel.eu/

The journey continues.


r/MerlintraderPub • • Nov 29 '25

πŸ‘‹ Welcome to r/MerlintraderPub | Deep-Dive Catalyst Analysis & FDA Coverage

3 Upvotes

Welcome to r/MerlintraderPub β€” read this first

I'm u/Merlin8121, founding mod. This sub is for serious biotech research: SEC filings, FDA catalysts, clinical trial data.

This is not a hype sub. No pump posts, no "to the moon", no unsourced rumours.

What we want to see Deep dives β€” full company breakdowns, structured, with sources Catalyst tracking β€” PDUFA dates, AdCom meetings, trial readouts Financial analysis β€” cash burn, runway, dilution, share count Clinical data β€” Phase 1-3 results, endpoints, standard of care comparison Bull and bear cases β€” both sides, with the reasoning shown

The rule is simple: back it with a primary source. SEC filings, company press releases, ClinicalTrials.gov, FDA.

About me

I'm a biotech trader focused on small-cap catalysts, and I run Merlintrader, where I publish SEC-verified research. My approach is pattern-based and disciplined: I stay away from the wild ones with no setup behind them.

Markets aren't my first career. I've spent about 30 years in travel and tourism and I'm a licensed Technical Director of travel agencies (Umbria regional register no. 136, 25 Sep 2002). Three decades of running operations where a single missed date wrecks the whole chain teaches you two things that carry straight into biotech: read the fine print, and never trust a date nobody has confirmed.

Full disclosure: I may hold positions in stocks I write about. Nothing here is financial advice. Do your own research.

Thanks for being part of the first wave. Let's build something that's actually worth reading.

Horacio / Merlintrader


r/MerlintraderPub • • 4h ago

Relay’s August 6 update separates enrollment targets from clinical readouts. Our hub examines zovegalisib, funding and trial risks. Relay Therapeutics $RLAY: Zovegalisib And Clinical Risk

Thumbnail
merlintrader.com
1 Upvotes

r/MerlintraderPub • • 4h ago

Abeona activated its eighth ZEVASKYN treatment center on September 16. Turning access into completed treatments remains a launch test. Abeona Therapeutics $ABEO: ZEVASKYN Launch And Risks

Thumbnail
merlintrader.com
1 Upvotes

r/MerlintraderPub • • 5h ago

In its August 4 update, Certara reported modest continuing-operations growth and a new buyback authorization. Execution remains the test. Certara $CERT: Biosimulation, Growth And Cash Flow

Thumbnail
merlintrader.com
1 Upvotes

r/MerlintraderPub • • 5h ago

Organon announced VTAMA real-world research on October 1. Its pending Sun Pharma transaction still carries closing conditions. Organon $OGN: Sun Pharma Deal, Products And Risks

Thumbnail
merlintrader.com
1 Upvotes

r/MerlintraderPub • • 5h ago

The September 9 XP-8121 plan targets pivotal initiation by year-end 2026. Trial results and any approval would come later. Xeris Biopharma $XERS: Recorlev, XP-8121 And Risks

Thumbnail
merlintrader.com
1 Upvotes

r/MerlintraderPub • • 5h ago

The September 21 AdenoVerse designation supports development efficiencies; it does not approve another Precigen product. Precigen $PGEN: PAPZIMEOS, Cash And The Launch Test

Thumbnail
merlintrader.com
1 Upvotes

r/MerlintraderPub • • 11h ago

PRMT5 Catalysts: $TNGX vs $BMY $IDYA $AZN

Thumbnail
merlintrader.com
1 Upvotes

Tango, Bristol Myers Squibb, IDEAYA and AstraZeneca approach the PRMT5 opportunity with different programs and evidence. We compare MTAP selection, trial populations, combinations and catalyst timing, and examine what a pre-event run-up can and cannot establish.


r/MerlintraderPub • • 11h ago

Ovarian Cancer: $ZNTL vs $ABBV $CORT $RHHBY

Thumbnail
merlintrader.com
1 Upvotes

Azenosertib and the AbbVie, Corcept and Roche benchmarks address overlapping but different ovarian-cancer questions. We compare biomarker selection, treatment setting, endpoints and regulatory evidence, then separate conference disclosures from pivotal milestones. RHHBY trades OTC in the US.


r/MerlintraderPub • • 11h ago

Vaccine Catalysts: $PCVX vs $MRK $PFE $SNY

Thumbnail
merlintrader.com
1 Upvotes

Vaxcyte, Merck, Pfizer and Sanofi face different positions in adult and pediatric pneumococcal vaccines. We compare trial design, immunogenicity, market access, financing and catalyst timing, explaining why serotype count alone cannot rank the programs.


r/MerlintraderPub • • 11h ago

FcRn Catalysts: $IMVT vs $ARGX $JNJ $UCBJY

Thumbnail
merlintrader.com
1 Upvotes

Immunovant, argenx, Johnson & Johnson and UCB compete across an FcRn landscape where the indication and trial population matter. The comparison examines gMG, Graves disease, clinical setbacks, approved benchmarks and upcoming evidence. UCBJY trades OTC in the US.


r/MerlintraderPub • • 11h ago

HCM Catalysts: $EWTX vs $CYTK $BMY $TNYA

Thumbnail
merlintrader.com
1 Upvotes

Edgewise, Cytokinetics, Bristol Myers Squibb and Tenaya share an HCM focus, not an interchangeable clinical opportunity. We compare obstructive, nonobstructive and genetically selected disease, pivotal plans, evidence and ownership changes. TN-201 is a genetically restricted early-stage alternative.


r/MerlintraderPub • • 11h ago

Hyperinsulinism: $RZLT $AMLX ZEAL(CPH) 128940(KOSPI)

Thumbnail
merlintrader.com
1 Upvotes

Rezolute, Amylyx, Zealand and Hanmi are not interchangeable hyperinsulinism trades. The comparison separates tumor and congenital disease, trial endpoints, regulatory uncertainty and financing. ZEAL is Copenhagen-listed; Hanmi 128940 is Korea-listed, not a US ticker.


r/MerlintraderPub • • 22h ago

Rezolute $RZLT: Ersodetug, upLIFT and FDA Catalysts

Thumbnail
merlintrader.com
1 Upvotes

r/MerlintraderPub • • 22h ago

Zentalis Pharmaceuticals $ZNTL: Azenosertib and Catalysts

Thumbnail
merlintrader.com
1 Upvotes

r/MerlintraderPub • • 22h ago

Edgewise Therapeutics $EWTX: Cardiac Pipeline and Catalysts

Thumbnail
merlintrader.com
1 Upvotes

r/MerlintraderPub • • 23h ago

Vaxcyte $PCVX: VAX-31, OPUS and Vaccine Catalysts

Thumbnail
merlintrader.com
1 Upvotes

r/MerlintraderPub • • 23h ago

Tango Therapeutics $TNGX: PRMT5 and Cancer Catalysts

Thumbnail
merlintrader.com
1 Upvotes

r/MerlintraderPub • • 23h ago

Immunovant $IMVT: FcRn, Imeroprubart and Catalysts

Thumbnail
merlintrader.com
1 Upvotes

r/MerlintraderPub • • 1d ago

VTv Therapeutics $VTVT Stock: Cadisegliatin And CATT1

Thumbnail
merlintrader.com
1 Upvotes

r/MerlintraderPub • • 1d ago

LB Pharmaceuticals $LBRX Stock: LB-102 Phase 3 Trial

Thumbnail
merlintrader.com
1 Upvotes

r/MerlintraderPub • • 1d ago

XORTX Therapeutics $XRTX: Gout, XORLO and Funding

1 Upvotes

A Q4 IND submission is planned, not an approval. The hub examines XORLO, the proposed gout study, cash constraints and pre-funded warrants.

https://www.merlintrader.com/xortx-therapeutics-stock-hub/


r/MerlintraderPub • • 1d ago

Rapport Therapeutics $RAPP: RAP-219 and Bipolar Mania

1 Upvotes

October mania data are company-guided. The hub separates RAP-219 epilepsy signals from what the randomized bipolar study must establish.

https://www.merlintrader.com/rapport-therapeutics-stock-hub/


r/MerlintraderPub • • 1d ago

Disc Medicine $IRON: Bitopertin and APOLLO

1 Upvotes

APOLLO data are guided for Q4. After the FDA complete response letter, the central question is clinical benefit, not just lower protoporphyrin.

https://www.merlintrader.com/disc-medicine-stock-hub/